Effects of XXXX on @entity1085 , intestinal transit, and serum deoxycholate: a prospective, randomised, double blind, placebo controlled trial.

@entity4392 @entity1 @entity1085 @entity2133 @entity5990 @entity6742 @entity2390 @entity3645 @entity1142 @entity6743 @entity165
BACKGROUND: @entity2390 inhibits @entity1085 and prolongs intestinal transit. This leads to increases in the proportion of @entity6743 in, and @entity165 saturation of, gall bladder bile, factors that contribute to the pathogenesis of @entity2390 induced @entity5990 . AIMS: To see if an intestinal prokinetic, @entity4392 , could overcome these adverse effects of @entity2390 and if so, be considered as a candidate prophylactic drug for preventing @entity1085 . METHODS: A randomised, double blind, placebo controlled, crossover design was used to examine the effects of @entity4392 (10 mg four times daily) on @entity1085 , mouth to caecum and large bowel transit times, and the proportions of @entity6743 and other @entity3645 , in fasting serum from: (i) control subjects (n=6), (ii) acromegalic @entity1 not treated with @entity2390 (n=6), (iii) acromegalics on long term @entity2390 (n=8), and (iv) @entity1 with @entity1142 (n=8). RESULTS: @entity4392 had no prokinetic effect on the gall bladder. In fact, it significantly increased both fasting and postprandial gall bladder volumes. However, it @entity2133 to caecum (from 176 (13) to 113 (11) minutes; p<0.001) and large bowel (from 50 (3.0) to 31 (3.4) h; p<0.001) transit times. It also reduced the proportion of @entity6743 in serum from 26 (2.3) to 15 (1.8)% (p<0.001), with a reciprocal increase in the proportion of @entity6742 from 40 (3.5) to 51 (3.8)% (p<0.01). There were significant linear relationships between large bowel transit time and the proportions of @entity6743 (r=0.81; p<0.001) and @entity6742 (r=-0.53; p<0.001) in fasting serum. INTERPRETATION/SUMMARY: @entity4392 failed to overcome the adverse effects of @entity2390 on @entity1085 but it countered @entity2390 induced prolongation of small and large bowel transit. Therefore, if changes in intestinal transit contribute to the development of @entity2390 induced @entity1085 , enterokinetics such as @entity4392 may prevent their formation.
